HMV Wealth Advisors LLC Has $418,000 Stake in Stryker Corporation $SYK

HMV Wealth Advisors LLC cut its position in Stryker Corporation (NYSE:SYK) by 54.8% in the 2nd quarter, Holdings Channel.com reports. The institutional investor owned 1,056 shares of the medical technology company’s stock after selling 1,279 shares during the quarter. HMV Wealth Advisors LLC’s holdings in Stryker were worth $418,000 at the end of the most recent reporting period.

Other large investors have also made changes to their positions in the company. Brighton Jones LLC raised its holdings in shares of Stryker by 15.4% during the 4th quarter. Brighton Jones LLC now owns 4,564 shares of the medical technology company’s stock worth $1,643,000 after buying an additional 609 shares in the last quarter. Vest Financial LLC bought a new position in Stryker in the first quarter valued at about $203,000. Wedmont Private Capital raised its stake in Stryker by 5.6% during the first quarter. Wedmont Private Capital now owns 3,876 shares of the medical technology company’s stock worth $1,358,000 after acquiring an additional 207 shares in the last quarter. Miracle Mile Advisors LLC lifted its holdings in shares of Stryker by 13.0% in the first quarter. Miracle Mile Advisors LLC now owns 7,569 shares of the medical technology company’s stock worth $2,818,000 after acquiring an additional 870 shares during the last quarter. Finally, Park Avenue Securities LLC grew its holdings in shares of Stryker by 9.3% during the 1st quarter. Park Avenue Securities LLC now owns 11,597 shares of the medical technology company’s stock valued at $4,317,000 after purchasing an additional 984 shares during the last quarter. Institutional investors and hedge funds own 77.09% of the company’s stock.

Analysts Set New Price Targets

Several equities analysts recently commented on the stock. Wells Fargo & Company increased their price objective on shares of Stryker from $435.00 to $445.00 and gave the company an “overweight” rating in a research note on Friday, August 1st. Redburn Partners set a $420.00 target price on Stryker in a research report on Thursday, September 18th. Wall Street Zen lowered shares of Stryker from a “buy” rating to a “hold” rating in a report on Friday, September 26th. Weiss Ratings reaffirmed a “buy (b-)” rating on shares of Stryker in a research note on Saturday, September 27th. Finally, Rothschild Redb raised shares of Stryker to a “hold” rating in a research note on Thursday, September 18th. Fifteen equities research analysts have rated the stock with a Buy rating and six have issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, Stryker currently has an average rating of “Moderate Buy” and an average target price of $430.33.

Stryker Stock Performance

Shares of Stryker stock opened at $365.99 on Tuesday. The business has a 50-day moving average price of $382.13 and a two-hundred day moving average price of $378.92. Stryker Corporation has a 1-year low of $329.16 and a 1-year high of $406.19. The company has a current ratio of 1.78, a quick ratio of 1.06 and a debt-to-equity ratio of 0.70. The company has a market cap of $139.92 billion, a P/E ratio of 48.48, a PEG ratio of 2.67 and a beta of 0.94.

Stryker (NYSE:SYK) last released its earnings results on Thursday, July 31st. The medical technology company reported $3.13 EPS for the quarter, topping the consensus estimate of $3.07 by $0.06. The business had revenue of $6.02 billion during the quarter, compared to analysts’ expectations of $5.92 billion. Stryker had a return on equity of 23.94% and a net margin of 12.25%.During the same quarter last year, the firm posted $2.81 earnings per share. The firm’s revenue was up 11.1% on a year-over-year basis. Stryker has set its FY 2025 guidance at 13.400-13.600 EPS. As a group, analysts anticipate that Stryker Corporation will post 13.47 EPS for the current year.

Stryker Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Friday, October 31st. Investors of record on Tuesday, September 30th will be given a dividend of $0.84 per share. This represents a $3.36 dividend on an annualized basis and a dividend yield of 0.9%. The ex-dividend date is Tuesday, September 30th. Stryker’s payout ratio is presently 44.50%.

Insider Buying and Selling at Stryker

In other Stryker news, Director Ronda E. Stryker sold 200,000 shares of the firm’s stock in a transaction on Wednesday, August 6th. The shares were sold at an average price of $376.45, for a total value of $75,290,000.00. Following the completion of the sale, the director directly owned 3,222,108 shares in the company, valued at approximately $1,212,962,556.60. This trade represents a 5.84% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, insider Viju Menon sold 500 shares of the company’s stock in a transaction dated Monday, August 25th. The shares were sold at an average price of $390.61, for a total transaction of $195,305.00. Following the transaction, the insider owned 12,511 shares in the company, valued at $4,886,921.71. This represents a 3.84% decrease in their position. The disclosure for this sale can be found here. 5.20% of the stock is owned by corporate insiders.

Stryker Company Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.